MedTrace Logo

Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma

NCT03450850 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-02-17

Study results available
· View outcomes & findings →

Summary

This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second line treatment and who have not previously received any BEV or any experimental agents.

Conditions

  • Astrocytoma, Grade III

Interventions

DEVICE

NOVOTTF-200A

NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.

Sponsors & Collaborators

  • NovoCure Ltd.

    collaborator INDUSTRY

  • Daniela A. Bota

    lead OTHER

Principal Investigators

  • Daniela Bota, MD · UC Irvine Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-21
Primary Completion
2023-09-07
Completion
2025-08-07
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03450850 on ClinicalTrials.gov